We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+0.11%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$65.2M
AUM Growth
-$43.3M
(-40%)
Cap. Flow
-$42.7M
Cap. Flow
% of AUM
-65.5%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
18
New
3
Increased
3
Reduced
2
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$11.2M |
| 2 |
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
|
+$6.19M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$2.07M |
| 4 |
Cencora
COR
|
+$1.67M |
| 5 |
Gilead Sciences
GILD
|
+$281K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Supernus Pharmaceuticals
SUPN
|
+$13.6M |
| 2 |
Cardinal Health
CAH
|
+$8.48M |
| 3 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$8.31M |
| 4 |
Elevance Health
ELV
|
+$8.09M |
| 5 |
Merck
MRK
|
+$8.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.82% |
| 2 | Financials | 17.41% |
| 3 | Industrials | 4.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AET
1
DELISTED
Aetna Inc
AET
| $11.4M | 17.41% |
+89,000
| New | +$11.2M |
|
|
2
Cencora
COR
$62B
| $11.2M | 17.1% |
126,000
+19,000
| +18% | +$1.67M |
|
|
3
Gilead Sciences
GILD
$165B
| $7.95M | 12.19% |
117,000
+4,000
| +4% | +$281K |
|
4
Anika Therapeutics
ANIK
$215M
| $7.89M | 12.1% |
181,573
+5,606
| +3% | +$268K |
|
5
Charles River Laboratories
CRL
$11.3B
| $7.7M | 11.81% |
85,612
-25,500
| -23% | -$2.17M |
|
6
McKesson
MCK
$104B
| $7.56M | 11.59% |
51,000
-6,000
| -11% | -$879K |
|
|
OSIR
7
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
| $5.47M | 8.39% |
+1,140,222
| New | +$6.19M |
|
|
GNC
8
DELISTED
GNC Holdings, Inc.
GNC
| $3.11M | 4.77% |
422,955
| – | – |
|
|
ACHN
9
DELISTED
Achillion Pharmaceuticals
ACHN
| $2.1M | 3.21% |
+497,807
| New | +$2.07M |
|
10
ImmuCell
ICCC
$99.6M
| $931K | 1.43% |
168,323
| – | – |
|
11
Alphatec Holdings
ATEC
$1.48B
| – | – |
-426,855
| Closed | -$1.37M |
|
|
12
Cardinal Health
CAH
$53.7B
| – | – |
-117,800
| Closed | -$8.48M |
|
|
13
Elevance Health
ELV
$81.5B
| – | – |
-56,300
| Closed | -$8.09M |
|
|
14
Merck
MRK
$322B
| – | – |
-142,633
| Closed | -$8.01M |
|
|
15
Supernus Pharmaceuticals
SUPN
$2.7B
| – | – |
-538,241
| Closed | -$13.6M |
|
|
TARO
16
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| – | – |
-78,905
| Closed | -$8.31M |
|
|
GTS
17
DELISTED
Triple-S Management Corporation
GTS
| – | – |
-382,767
| Closed | -$7.54M |
|
|
ELOS
18
DELISTED
Syneron Medical Ltd
ELOS
| – | – |
-706,107
| Closed | -$5.93M |
|
Similar funds
KP
AWA
TCM
SAAM
SC
PAA
PC
BOCH
HealthInvest Partners's Q1 2017 Portfolio in Review
As of Q1 2017, HealthInvest Partners held 18 positions worth $65.2M, down 40% from $109M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
HealthInvest Partners withdrew a net $42.7M in Q1 2017, closing 8 positions and reducing 2 holdings. Its most notable exit was Supernus Pharmaceuticals, an estimated $13.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 83% a quarter earlier, followed by Financials and Industrials.
Against the trend, HealthInvest Partners opened a new position in Aetna Inc worth $11.4M.
- HealthInvest Partners's largest Q1 2017 buy was Aetna Inc: 89,000 shares worth $11.4M.
- HealthInvest Partners added most to Cencora in Q1 2017, an estimated $1.67M increase.
- HealthInvest Partners's biggest Q1 2017 reduction was Charles River Laboratories, cutting an estimated $2.17M.
- HealthInvest Partners fully exited Supernus Pharmaceuticals in Q1 2017, selling an estimated $13.6M.
- HealthInvest Partners's ten largest holdings make up 100% of its $65.2M portfolio in Q1 2017.
- HealthInvest Partners opened 3 new positions and closed 8 in Q1 2017.
- HealthInvest Partners's portfolio value fell 40% quarter-over-quarter to $65.2M.
Based on HealthInvest Partners's 13F filing for Q1 2017, filed 28 Apr 2017.